NOT KNOWN FACTUAL STATEMENTS ABOUT PHASE 3 STUDY OF PEMBROLIZUMAB

Keytruda is a brand (trade) name for pembrolizumab. It's given by intravenous infusion every three to six weeks. Not often, the usage of Keytruda results from the immune system attacking nutritious tissues which can cause critical side effects such as pneumonitis, colitis, or hepatitis. In many people, the use of Keytruda has resulted within the re